CELVER

K111382 · Cellulose Concepts, LLC · FRO · May 31, 2012 · SU

Device Facts

Record IDK111382
Device NameCELVER
ApplicantCellulose Concepts, LLC
Product CodeFRO · SU
Decision DateMay 31, 2012
DecisionSESE
Submission TypeTraditional
Device ClassClass U
AttributesTherapeutic

Intended Use

For prescription use, under the supervision of a health care professional, CELVER® may be used for the management of partial thickness (second degree) burns, diabetic foot ulcers, leg ulcers (venous stasis ulcers, arterial ulcer and leg ulcers of mixed aetiology) and pressure ulcers/sores (partial & full thickness). For over-the-counter use, CELVER® may be used for minor abrasions, minor lacerations, minor cuts, minor scalds and 1st degree burns.

Device Story

CELVER® is a sterile, silver-containing moist wound dressing. Composition includes sodium carboxymethylcellulose, sodium lactate, and ionic silver embedded in a 100% cotton non-woven substrate. Upon contact with wound exudate, the dressing forms a soft, cohesive gel, maintaining a moist healing environment and facilitating easy removal. Dimensions are 4" x 4", perforated into 15 sections for flexibility. Used in clinical settings under professional supervision or by patients for minor wounds. The device provides a physical barrier and antimicrobial properties via ionic silver to support wound healing.

Clinical Evidence

Bench testing only. Biocompatibility testing performed per ISO 10993-10:2002 and ISO 10993-5:2009. Device passed all pre-determined pass/fail criteria.

Technological Characteristics

Sterile wound dressing; materials: sodium carboxymethylcellulose, sodium lactate, ionic silver, 100% cotton non-woven substrate. Dimensions: 4" x 4" perforated into 15 sections. Biocompatibility tested per ISO 10993-10:2002 and ISO 10993-5:2009.

Indications for Use

Indicated for management of partial thickness (2nd degree) burns, diabetic foot ulcers, leg ulcers (venous stasis, arterial, mixed), and pressure ulcers (partial/full thickness) under professional supervision; also indicated for OTC use for minor abrasions, lacerations, cuts, scalds, and 1st degree burns.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Attachment 2 ﺔ ﺍﻟﻤﺮﺍﺟﻊ MAY 3 1 2012 ## 510(K) SUMMARY This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92. The assigned 510(k) number is:___k111382 #### Submitter's Identification: 1. Cellulose Concepts LLC 2867 Industrial Plaza Drive, Suite C Tallahassee, FL 32301 Phone: 850 391 9859 Date Summary Prepared: December 6, 2011 #### Name of the Device: 2. Proprietary name: CELVER® - Unclassified 3. Classification: FRO Product Code: #### Common or Usual Name: 4. Common Name: Absorbent Antimicrobial Wound Dressing #### Predicate Device Information: 5. K013814 ConvaTec Absorbent Antimicrobial Wound Dressing #### 6. Description: CELVER® is a sterile silver moist wound dressing. CELVER® is composed of sodium carboxymethylcellulose, sodium lactate and ionic silver imbedded into a non-woven 100% cotton substrate. In contact with wound exudate, the highly adsorbent dressing creates a soft cohesive gel that forms an intimate contact with the wound surface and maintains a moist wound-healing environment. The construction of the bandage provides for easy removal with minimal Page \\$\frac{1}{4}^2\$ {1}------------------------------------------------ residue left on the wound. The bandage dimensions are 4" x 4" and is further perforated into 15 equal sections appropriately ¾" x 1 ½" for flexibility and ease of use. #### 7. Intended Use: For prescription use, under the supervision of a health care professional, CELVER® may be used for the management of partial thickness (second degree) burns, diabetic foot ulcers, leg ulcers (venous stasis ulcers, arterial ulcer and leg ulcers of mixed aetiology) and pressure ulcers/sores (partial & full thickness). #### Comparison to Predicate: 8. The predicate device and CELVER® are indicated for acute and chronic wounds. Both dressings are of a similar composition consisting of silver and absorbent padding to absorb wound exudate, and create a moist wound environment supportive of the healing process. #### Performance Data: 9. Non-clinical: Verification, validation, and testing activities were conducted to establish the performance, functionality, and reliability characteristics of the CELVER® with respect to the predicate device. Third party testing was performed including biocompatibility testing per ISO 10993-10:2002 and ISO10993-5:2009 The device passed all of the tests based on pre-determined Pass/Fail criteria. #### 10. Conclusions: The data from the biocompatibility and non clinical tests show that the CELVER®is as safe and effective as the legally marketed predicate device. Therefore we conclude that the CELVER®is substantially equivalent to the predicate device. 2 2 Page & of A {2}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular emblem with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Cellulose Concepts, LLC % MDI Consultants, Incorporated Ms. Maria F. Griffin 55 Northern Boulevard, Suite 200 Great Neck, New York 11021 Re: K111382 Trade/Device Name: CELVER Regulation Class: Unclassified Product Code: FRO Dated: May 17, 2012 Received: May 21, 2012 Dear Ms. Griffin: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical MAY 3 1 2012 {3}------------------------------------------------ ## Page 2 - Ms. Griffin device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # INDICATIONS FOR USE 510(k) Number (if known): Device Name: CELVER® Indications For Use: For over-the-counter use, CELVER® may be used for minor abrasions, minor lacerations, minor cuts, minor scalds and 1st degree burns. Prescription Use Over-The Counter Use (Per 21 CFR 801 Subpart D) OR (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Daniel Kiene for MM (Division Sign Jil) Division of Surgical. Orthopedic. and Restorative Devices 510(k) Number K111382 {5}------------------------------------------------ ## INDICATIONS FOR USE 510(k) Number (if known): k111382 Device Name: CELVER® Indications For Use: For prescription use, under the supervision of a health care professional, CELVER® may be used for the management of partial thickness (second degree) burns, diabetic foot ulcers, leg ulcers (venous stasis ulcers, arterial ulcer and leg ulcers of mixed aetiology) and pressure ulcers/sores (partial & full thickness). Prescription Use _ X (Per 21 CFR 801 Subpart D) OR Over-The Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) David Kaniebaum MM (Division Sign-Off) Division of Surgical. Orinopedic, and Restorative Devices 510(k) Number K11382 Page 2 of 2
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%